संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

stratus pharmaceuticals inc - castor oil (unii: d5340y2i9g) (castor oil - unii:d5340y2i9g) - castor oil 788 mg in 1 g - venelex™ ointment is a wound dressing for topical use in the management of chronic and acute wounds, and dermal ulcers including: pressure ulcers (stage i-iv), venous stasis ulcers, diabetic ulcers, first and second degree burns, surgical wounds, traumatic wounds, superficial wounds, ulcers resulting from arterial insufficiency and grafted wound/donor sites. venelex™ ointment is contraindicated in persons who have shown hypersensitivity to balsam peru, petrolatum or any of the other ingredients used in this ointment. venelex™ ointment is easy to apply and quickly reduces odors frequently accompanying a decubitus ulcer. the wound may be left open or appropriate dressing applied. please note that wounds generally heal poorly in the presence of hemoglobin or zinc deficiency.

भारत - अंग्रेज़ी - Central Drugs Standard Control Organization

axyzen life - lycopene - syr - with antioxidant - 200ml

भारत - अंग्रेज़ी - Central Drugs Standard Control Organization

axyzen life - lycopene - cap - 2000mcg( with antioxidants) - 10*1*10

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - cefalexin monohydrate, quantity: 262.94 mg (equivalent: cefalexin, qty 250 mg) - capsule - excipient ingredients: lactose; magnesium stearate; colloidal anhydrous silica; titanium dioxide; brilliant blue fcf; purified water; quinoline yellow; allura red ac; gelatin; sodium lauryl sulfate - cephalexin is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms:,- respiratory tract infections caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.),- bacterial sinusitis caused by streptococci, s. pneumoniae and s. aureus (methicillin-sensitive only),- otitis media due to s. pneumoniae, staphylococci,- skin and soft-tissue infections caused by staphylococci and/or streptococci,- genitourinary tract infections, including acute prostatitis caused by e. coli, p. mirabilis, and klebsiella sp.,the effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin is not indicated in these conditions.,note: appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin. renal function studies should be performed when indicated.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - cefalexin monohydrate, quantity: 525.87 mg (equivalent: cefalexin, qty 500 mg) - capsule - excipient ingredients: lactose; magnesium stearate; colloidal anhydrous silica; titanium dioxide; brilliant blue fcf; quinoline yellow; purified water; gelatin; sodium lauryl sulfate - cephalexin is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms:,- respiratory tract infections caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.),- bacterial sinusitis caused by streptococci, s. pneumoniae and s. aureus (methicillin-sensitive only),- otitis media due to s. pneumoniae, staphylococci,- skin and soft-tissue infections caused by staphylococci and/or streptococci,- genitourinary tract infections, including acute prostatitis caused by e. coli, p. mirabilis, and klebsiella sp.,the effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin is not indicated in these conditions.,note: appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin. renal function studies should be performed when indicated.

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - cefalexin monohydrate 27.602 mg/ml equivalent to cephalexin 25 mg/ml (+5% stability overage);   - granules for oral suspension - 125 mg/5ml - active: cefalexin monohydrate 27.602 mg/ml equivalent to cephalexin 25 mg/ml (+5% stability overage)   excipient: apple flavour 648601 citric acid guar gum iron oxide yellow raspberry flavour 501183 tp0551 saccharin sodium simeticone sodium benzoate strawberry flavour 052303 bp0551 sucrose tutti frutti flavour 051880 ap0551 - cefalexin is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: · bacterial sinusitis caused by streptococci, streptococcus pneumoniae, and staphylococcus aureus (methicillin -sensitive only); ·respiratory tract infections caused by s. pneumoniae and streptococcus pyogenes (penicillin is the usual medicine of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever - cefalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefalexin in the subsequent prevention of either rheumatic fever or bacterial endocarditis are not available at present); · otitis media due to s. pneumoniae, haemophilus influenzae, staphylococci, streptococci, and moraxella catarrhalis; · skin and skin-structure infections caused by staphylococci and/or streptococci; · bone infections caused by staphylococci and/or proteus mirabilis; · genitourinary tract infections, including acute prostatitis, caused by eschericia coli, p. mirabilis, and klebsiella pneumoniae; · dental infections caused by staphylococci and/or streptococci. note - culture and susceptibility tests should be initiated prior to and during therapy. renal function studies should be performed when indicated.

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - cefalexin monohydrate 55.206 mg/ml equivalent to cephalexin 50 mg/ml (+5% stability overage);   - granules for oral suspension - 250 mg/5ml - active: cefalexin monohydrate 55.206 mg/ml equivalent to cephalexin 50 mg/ml (+5% stability overage)   excipient: apple flavour 648601 citric acid guar gum iron oxide yellow raspberry flavour 501183 tp0551 saccharin sodium simeticone sodium benzoate strawberry flavour 052303 bp0551 sucrose tutti frutti flavour 051880 ap0551 - cefalexin is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: · bacterial sinusitis caused by streptococci, streptococcus pneumoniae, and staphylococcus aureus (methicillin -sensitive only); ·respiratory tract infections caused by s. pneumoniae and streptococcus pyogenes (penicillin is the usual medicine of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever - cefalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefalexin in the subsequent prevention of either rheumatic fever or bacterial endocarditis are not available at present); · otitis media due to s. pneumoniae, haemophilus influenzae, staphylococci, streptococci, and moraxella catarrhalis; · skin and skin-structure infections caused by staphylococci and/or streptococci; · bone infections caused by staphylococci and/or proteus mirabilis; · genitourinary tract infections, including acute prostatitis, caused by eschericia coli, p. mirabilis, and klebsiella pneumoniae; · dental infections caused by staphylococci and/or streptococci. note - culture and susceptibility tests should be initiated prior to and during therapy. renal function studies should be performed when indicated.

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - celecoxib (unii: jcx84q7j1l) (celecoxib - unii:jcx84q7j1l) - celecoxib 200 mg - celecoxib capsules are  indicated for the management of the signs and symptoms of oa [see clinical studies (14.1) ] for the management of the signs and symptoms of ra [see clinical studies (14.2) ] for the management of the signs and symptoms of jra in patients 2 years and older [see clinical studies (14.3) ] for the management of the signs and symptoms of as [see clinical studies (14.4) ] for the management of acute pain in adults [see clinical studies (14.5) ] for  the   management   of   primary   dysmenorrhea  [see  clinical  studies  (14.5) ] celecoxib capsules are contraindicated in the following patients: pregnancy category c. pregnancy category d from 30 weeks of gestation onward. risk summary use of nsaids, including celecoxib, during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. avoid use of nsaids, including celecoxib, in pregnant women starting at 30 weeks of gestation. there are no adequate and well-controlled studies of celec

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

trigen laboratories, llc - celecoxib (unii: jcx84q7j1l) (celecoxib - unii:jcx84q7j1l) - celecoxib 50 mg - celecoxib is indicated for the management of the signs and symptoms of oa [see clinical studies (14.1) ] for the management of the signs and symptoms of ra [see clinical studies (14.2) ] for the management of the signs and symptoms of jra in patients 2 years and older [see clinical studies (14.3) ] for the management of the signs and symptoms of as [see clinical studies (14.4) ] for the management of acute pain in adults [see clinical studies (14.5) ] for the management of primary dysmenorrhea [see clinical studies (14.5) ] celecoxib is contraindicated in the following patients: ·               known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions)to celecoxib, any components of the drug product [see warnings and precautions (5.7,   5.9) ]. ·               history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other   nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids, have been        reported in such patients [see warnings and precauti

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - celecoxib, quantity: 200 mg - capsule, hard - excipient ingredients: lactose monohydrate; sodium lauryl sulfate; gelatin; titanium dioxide; croscarmellose sodium; magnesium stearate; povidone; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; iron oxide yellow; shellac; strong ammonia solution - celecoxib is indicated for the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.,celecoxib is indicated for the treatment of primary dysmenorrhoea in adults.,celecoxib is indicated for the short-term treatment of acute pain in adults following surgery or musculoskeletal and/or soft tissue injury.